Skip to main content English


Öykü Özer
Öykü Özer, MSc.

Department of Biomedical Imaging and Image-guided Therapy (Division of Nuclear Medicine)
Position: Research Assistant

ORCID: 0009-0009-0770-4354
T +43 1 +43 69919156426


Cachexia; Carcinoma, Non-Small-Cell Lung; Clinical Immunology; Immunotherapy; Inflammation; Metabolic Networks and Pathways; Metabolomics; Molecular Imaging; Neuroimaging; Oncology; Positron-Emission Tomography; Stress, Physiological; Transcriptome; Translational Medical Research; Tumor Microenvironment

Research group(s)

Research interests

My research focuses on understanding the complex interplay between chronic stress, immune dynamics and cachexia in lung cancer progression and how these factors affect treatment responses. By integrating clinical data from both healthy individuals and lung cancer patients with experimental findings derived from genetically engineered mouse models, I aim to discover potential biomarkers and novel therapeutic targets and translate the findings back and forwards.The primary focus lies in understanding how stress influences the tumor microenvironment (TME) and immune metabolism, thereby impacting the efficacy of immunotherapies. Additionally, a focus of my work is total body PET and the validation of metabolic phenotypes e.g. how chronic stress related brain patterns are correlated in these intricate dynamics.

Through a translational approach, I aim to bridge gaps between observational clinical data and underlying molecular mechanisms, ultimately contributing to enhanced strategies in therapeutic interventions in oncology. Furthermore, the findings are also intended to be applicable to other types of cancer, increasing the translational impact of my research.

Techniques, methods & infrastructure

·       Preclinical Imaging µPET/µCT (Metabolic, Oncological and Neuro Imaging)

·       Image Analysis (πPMOD)

·       ex-vivo Biodistribution Studies

·       Imaging Organ-Axis/Organ-Crosstalk

·       (Bio)analytical Methods (ELISA, qPCR, Flow Cytometry, IHC, AURA, Western blot...)

·       Immunotherapy

·       Preclinical Cancer Mouse models

·       Human Clinical Studies (Sample Collection, Analysis, Biobanking… )

Selected publications

  1. Mir Seyed Nazari, P. et al. (2019) ‘Low Systemic Levels of Chemokine C-C Motif Ligand 3 (CCL3) are Associated with a High Risk of Venous Thromboembolism in Patients with Glioma’, Cancers, 11(12), p. 2020. Available at: